NCT06515184

Coenzyme Q10 for Gulf War Illness: A Replication Study

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (estimated)
• Sponsor: University of California, San Diego · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.

Conditions

• Gulf War Syndrome
• Persian Gulf Syndrome
• Mitochondrial Disorder, Respiratory Chain

Interventions

Type	Name	Description
DRUG	PharmaNord Bio-Quinone Active CoQ10 Gold 100mg	Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.
DRUG	PharmaNord Placebo	Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.
DRUG	PharmaNord Bio-Quinone Active CoQ10 Gold 100mg	Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime. Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option "drug" was chosen as the closest permissible option.

Timeline

• Start date: 2024-09-13
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2024-07-23
• Last updated: 2024-11-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study